Response to Sorafenib at a Low Dose in Patients with Radioiodine-Refractory Pulmonary Metastases from Papillary Thyroid Carcinoma

Thyroid ◽  
2011 ◽  
Vol 21 (2) ◽  
pp. 119-124 ◽  
Author(s):  
Libo Chen ◽  
Yan Shen ◽  
Quanyong Luo ◽  
Yongli Yu ◽  
Hankui Lu ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Low Dose ◽  
Pulmonary Metastases ◽  
Papillary Thyroid

scholarly journals Ablation therapy using a low dose of radioiodine may be sufficient in low- to intermediate-risk patients with follicular variant papillary thyroid carcinoma

2020 ◽  
Vol 48 (11) ◽  
pp. 030006052096649
Author(s):  
Fuxin Li ◽  
Wei Li ◽  
Katherine D. Gray ◽  
Rasa Zarnegar ◽  
Dan Wang ◽  
...  
Keyword(s):  
Lymph Node ◽  
Papillary Thyroid Carcinoma ◽  
Local Recurrence ◽  
Thyroid Carcinoma ◽  
Low Dose ◽  
High Dose ◽  
Intermediate Risk ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
Remnant Ablation

Objectives Follicular variant papillary thyroid carcinoma (FVPTC) is treated similarly to classical variant papillary thyroid carcinoma (cPTC). However, FVPTC has unique tumour features and behaviours. We investigated whether a low dose of radioiodine was as effective as a high dose for remnant ablation in patients with FVPTC and evaluated the recurrence of low-intermediate risk FVPTC. Methods Data from cPTC and FVPTC patients treated with I-131 from 2004 to 2014 were reviewed. Demographics, tumour behaviour, lymph node metastasis, and local recurrence data were compared between FVPTC and cPTC patients. Then, low-intermediate risk FVPTC patients were divided into low, intermediate, and high I-131 dose groups, and postoperative I-131 activities were analysed to evaluate the effectiveness of I-131 therapy for thyroid remnant ablation. Results In total, 799 cases of FVPTC (n = 168) and cPTC (n = 631) treated with I-131 were identified. Patients with FVPTC had a larger primary nodule size than cPTC, but lymph node metastases and local recurrence were more prevalent in cPTC than in FVPTC. For the low-, intermediate-, and high-dose groups, success rates of ablation did not differ (82.0%, 80%, and 81.3%, respectively). Conclusion FVPTC differs from cPTC in behaviour. Low-dose ablation may be sufficient in FVPTC patients with low-intermediate disease risk.

Childhood Papillary Thyroid Carcinoma With Miliary Pulmonary Metastases

2006 ◽  
Vol 24 (36) ◽  
pp. 5788-5789 ◽  
Author(s):  
Josephina C.J. Vermeer-Mens ◽  
Natascha N.T. Goemaere ◽  
Vibeke Kuenen-Boumeester ◽  
Sabine M.P.F. de Muinck Keizer-Schrama ◽  
Christian M. Zwaan ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Pulmonary Metastases ◽  
Papillary Thyroid

scholarly journals Management of Papillary Carcinoma of Thyroid with Pulmonary Metastases in Institute of Nuclear Medicine and Allied Sciences, Rajshahi – Two Case Reports

2018 ◽  
Vol 18 (2) ◽  
pp. 179-182
Author(s):  
Md Kabiruzzaman Shah ◽  
Nasrin Begum ◽  
Mosharof Hossain ◽  
Parvez Ahmed ◽  
Sariful Islam Chawdhuary ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Papillary Carcinoma ◽  
Radioactive Iodine ◽  
Pulmonary Metastases ◽  
Case Reports ◽  
Young Patients ◽  
Radioactive Iodine Therapy ◽  
Papillary Thyroid

Papillary thyroid carcinoma with pulmonary metastasis is relatively uncommon which can be treated with radioactive iodine therapy. Here, our experiences with two cases of papillary thyroid carcinoma with pulmonary metastases in young patients are discussed.Bangladesh J. Nuclear Med. 18(2): 179-182, July 2015

scholarly journals Synchronous Lung Adenocarcinoma and Papillary Thyroid Carcinoma - The Metastases at the Centre of the Discussion

2021 ◽  
Author(s):  
Joana Ferra ◽  
Cátia Guimarães ◽  
Cristina Matos ◽  
Fernando Nogueira
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Lung Adenocarcinoma ◽  
Kinase Inhibitor ◽  
Pulmonary Metastases ◽  
Lung Metastases ◽  
Stage Iv ◽  
Pathological Examination ◽  
Papillary Thyroid ◽  
Patient Prognosis

Synchronous tumours are defined as two or more independent primary neoplasms of different origins diagnosed at the same time in 1 individual. Although rare, its incidence is increasing and the proper diagnosis and staging of each tumour is crucial in defining the patient prognosis and the best therapeutic choice. We present a case of a 56-year-old woman presenting with a lung adenocarcinoma and pulmonary metastases initially diagnosed as stage IV and who was started on a tyrosine kinase inhibitor (erlotinib). In the meantime, she was also diagnosed with papillary thyroid carcinoma and was submitted to complete thyroidectomy. After 6 cycles of erlotinib, thoracic CT showed a decrease in the dimensions of the primary pulmonary tumour, but an increase in the size and number of pulmonary metastases while blood tests showed elevated thyroglobulin. This therefore raised the possibility that the metastases could have originated from the thyroid carcinoma. Anatomo-pathological examination of the lung metastases confirmed this hypothesis. In conclusion, it is important to confirm the origin of metastases in synchronous tumours given this can lead to a re-staging of tumours and a different prognosis, along with other therapeutic options. A multidisciplinary team meeting is crucial to define management and therapeutic approaches for these patients.

Preoperative scintigraphic visualization of lymph nodes and pulmonary metastases from papillary thyroid carcinoma

2004 ◽  
Vol 18 (1) ◽  
pp. 59-62 ◽  
Author(s):  
Sami Boughattas ◽  
Habib Hassine ◽  
Kaouther Chatti ◽  
Maryem Degdegui ◽  
Habib Essabbah ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Lymph Nodes ◽  
Pulmonary Metastases ◽  
Papillary Thyroid
Sign in / Sign up

Export Citation Format

Share Document